US Pharma MarketingThe CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
Source: BioPharma Dive